Based on the robust results, we are are confident of achieving our full-year objectives for new record sales and earnings.
We first want to fix the quality and quantity problems which are at hand.
Our increased level of investment in marketing and sales, with the priority on key growth drivers, resulted in a sales growth of 21 percent in Pharmaceuticals in the U.S.,
Our plan is to turn around the Chiron vaccines business, which will require investments in R&D and manufacturing to increase quality and capacity.
Market growth in 2006 will slow down somewhat. I expect that we will be able to continue to gain market share.
At present, no collaboration has been discussed with Roche management, although we hope that over time we will be able to explore areas of collaboration.
Litigation is potentially much larger when you vaccinate healthy people.
We are confident of delivering in 2006 another year of dynamic growth with record sales and earnings.
Looking ahead, we anticipate a somewhat softer third quarter and, again, a more dynamic fourth quarter resulting in mid-single-digit sales growth... and solid operating growth for the full year.
Copyright © 2024 Electric Goat Media. All Rights Reserved.